Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Gains from Sales and Divestitures: 2018-2025

Historic Gains from Sales and Divestitures for Whitehawk Therapeutics (WHWK) over the last 1 years, with Sep 2025 value amounting to $387,925.

  • Whitehawk Therapeutics' Gains from Sales and Divestitures was N/A to $387,925 in Q3 2025 from the same period last year, while for Sep 2025 it was $387,925, marking a year-over-year change of. This contributed to the annual value of $149,243 for FY2018, which is N/A change from last year.
  • As of Q3 2025, Whitehawk Therapeutics' Gains from Sales and Divestitures stood at $387,925, which was down 0.00% from $387,925 recorded in Q2 2025.
  • Whitehawk Therapeutics' 5-year Gains from Sales and Divestitures high stood at $387,925 for Q2 2025, and its period low was $387,925 during Q2 2025.
  • Moreover, its 1-year median value for Gains from Sales and Divestitures was $387,925 (2025), whereas its average is $387,925.